Monday 21 Jan, 2019 05:09 PM
Site map | Locate Us | Login
   ITI spurts after new order win    Kotak Mahindra Bank advances after good Q3 outcome    South Indian Bank Ltd leads losers in 'A' group    Vivimed Labs Ltd leads losers in 'B' group    Volumes spurt at Shriram City Union Finance Ltd counter    Tech Mahindra Ltd gains for third straight session    Mindtree Ltd soars 2.14%, Gains for third straight session    Tata Consultancy Services Ltd up for fifth session    Sun Pharma Advanced Research Company Ltd leads gainers in 'A' group    Wipro drops after declaring Q3 result     Volumes jump at Shriram Transport Finance Company Ltd counter    HDFC Bank gains after good Q3 outcome    Larsen & Toubro Ltd Slides 2.01%, S&P BSE Capital Goods index Shed 1.13%    NTPC rises as board to consider bonus shares    Sun Pharma Advanced Research Company Ltd Spikes 3.91% 
Saravan Stocks
Hot Pursuit
Scrips, which has significant changes during the market hours.
Granules India spurts after USFDA approval for generic
17-May-18   11:07 Hrs IST

The announcement was made before trading hours today, 17 May 2018.

Meanwhile, the S&P BSE Sensex was down 89.05 points, or 0.25% to 35,298.83.

On the BSE, 5.17 lakh shares were traded in the counter so far compared with average daily volumes of 2.30 lakh shares in the past two weeks. The stock had hit a high of Rs 106.30 and a low of Rs 97.65 so far during the day. The stock hit a 52-week high of Rs 157 on 18 May 2017. The stock hit a 52-week low of Rs 91.30 on 14 May 2018.

Granules India announced that the US Food and Drug Administration (USFDA) has approved its Abbreviated New Drug Applications (ANDA) for Methylergonovine 0.2 mg tablets. The ANDA was filed by Granules Pharmaceuticals Inc., a wholly-owned subsidiary of Granules India. The approved ANDA is the bioequivalent to the reference listed drug product (RLD), Methergine 0.2 mg. Methylergonovine is a semi—synthetic ergot alkaloid used for the prevention and control of postpartum haemorrhage.

On a consolidated basis, net profit of Granules India declined 10.34% to Rs 35.02 crore on 16.30% rise in net sales to Rs 410.73 crore in Q3 December 2017 over Q3 December 2016.

Granules India is a pharmaceutical manufacturing company. It produces finished dosages, pharmaceutical formulation intermediates and active pharmaceutical ingredients. The company's global presence extends to over 250 customers in 60 countries through offices in India, US, and UK.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID:       Customers grievances :     Compliance officer : Mr.G Anand ,
Hit Count : 10269931
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016  |  MCX : INZ000081736
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 12815 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. Saravana Stocks Pvt. Ltd